Form 8-K - Current report:
SEC Accession No. 0001104659-25-044223
Filing Date
2025-05-02
Accepted
2025-05-02 17:15:43
Documents
13
Period of Report
2025-04-29
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2513612d1_8k.htm   iXBRL 8-K 26071
  Complete submission text file 0001104659-25-044223.txt   199421

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA eyen-20250429.xsd EX-101.SCH 3014
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE eyen-20250429_lab.xml EX-101.LAB 34239
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eyen-20250429_pre.xml EX-101.PRE 22358
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2513612d1_8k_htm.xml XML 3675
Mailing Address 295 MADISON AVENUE, SUITE 2400 NEW YORK NY 10017
Business Address 295 MADISON AVENUE, SUITE 2400 NEW YORK NY 10017 813-766-9539
EYENOVIA, INC. (Filer) CIK: 0001682639 (see all company filings)

EIN.: 471178401 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38365 | Film No.: 25909947
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)